Lumos Diagnostics Holdings Ltd. · ASX:LDX
Lumos Diagnostics — FY2023 Earnings Presentation
21 slides from Lumos Diagnostics's earnings presentation, Aug 30, 2023
Slide 1: FY2023 Results Presentation
Lumos Diagnostics Holdings Limited FY2023 Results Presentation August 2023 www.lumosdiagnostics.com Confidential. This document and supporting materials contain confidential and proprietary business information from Lumos. 1
Slide 2: Disclaimer and Important Information
Disclaimer and Important Information This presentation (Presentation) has been prepared solely for informational purposes by Lumos Diagnostics Holdings Limited (Company). The information contained in this document (“Document”) has been prepared by Lumos Diagnostics Holdings Limited (referred to as “
Slide 3: FY23 Summary
FY23 Summary “ The opportunity that Lumos has with its technology, know-how and expertise in the development US$10.5 million total revenue in FY23 and production of point-of-care diagnostic tests and its unique US$10.2 million Commercial Services revenue in FY23 9% increase vs FY22 reader platform r
Slide 4: Company Overview
Company Overview
Slide 5: Company Snapshot
Company Snapshot Lumos is a fully-integrated developer and manufacturer of connected, rapid, point-of-care tests for the diagnostics and healthcare industries • Led by Doug Ward, industry veteran with over 30 years experience in diagnostics • Comprehensive offering from concept design to clinical to
Slide 6: Board of Directors
Board of Directors Sam Lanyon Doug Ward Bronwyn Le Grice Lawrence Mehren Catherine Robson Non-Executive CEO and Non-Executive Non-Executive Non-Executive Chair Managing Director Director Director Director 6
Slide 7: Lumos has a compelling and highly competitive offering
Lumos has a compelling and highly competitive offering 1. Fully-integrated—from design to manufacturing 2. Proprietary reader platform for use in different settings Strategic Product Commercial Innovation Development Manufacturing Single-use Multi-use disposable Desktop readers 3. IVD development an
Slide 8: Lumos' POC diagnostic test development engine
Lumos’ POC diagnostic test development engine Design Develop Manufacture Product concepts REVENUE Contract Fees Margin Sales & license payments STREAMS from services from manufacturing from own & other products 8
Slide 9: Favourable industry structure and key trends
Favourable industry structure and key trends Robust underlying category growth forecast GLOBAL POC DIAGNOSTIC TEST SALES • Significant growth anticipated from growing role of diagnostic tests in healthcare • Rapid, point-of-care tests increasingly being used – common in US settings (US$ in billions)
Slide 10: Strategic partnerships are a key pillar of Lumos' growth plan
Strategic partnerships are a key pillar of Lumos’ growth plan Lumos provides a compelling service offering for leading diagnostics companies • Fully-integrated offering—from concept-to-clinic-to-commercial production • Proprietary reader platform—integrate POC testing with electronic medical records
Slide 11: Commercial Services - FY23 Operational Summary
Commercial Services - FY23 Operational Summary • Lumos commercial services revenue of US$10.2 million – an increase of 9% from FY22 • Completed major reorganisation which included reduction of headcount by over 60% • Closed Sarasota FL facility and consolidated operations to single site in Carlsbad
Slide 12: Lumos has established a strategic partnership with Hologic
Lumos has established a strategic partnership with Hologic • Hologic is a recognized global leader in women’s health based in Massachusetts - NASDAQ: HOLX, Market Capitalization US$20 billion - FY2022 revenue of US$4.2 billion with net income of US$1.3 billion - Diagnostic products account for >50%
Slide 13: Lumos Products - FY23 Summary
Lumos Products - FY23 Summary • Product sales of $0.3 million vs $2.2 million in FY2022 – reduction due to absence of $1.7 million in pandemic-related sales of CoviDx™ and lower sales and marketing investment • Secured FDA clearance to market FebriDx® test in the United States at the end of FY2023 f
Slide 14: FY23 Results
FY23 Results
Slide 15: FY23 – Result Highlights
FY23 – Result Highlights* “ While Lumos went into Revenue $10.5 million ($11.6 million FY22, incl. CoviDx $1.7m), revenue from services up 9% FY2023 facing a number of challenges, I am extremely Gross profit margin for FY23 of 56%, an improvement of 12% over FY22 happy with the successes we achieved
Slide 16: Revenue & Gross Profit
Revenue & Gross Profit (US$ in thousands) REVENUE REVENUE MIX GROSS PROFIT $6,428 100% $6,000 $5,448 $4,000 $3,376 70% $5,202 $5,087 80% $3,500 $2,571 $2,571 $2,596 62% 60% $5,000 $3,000 49% 50% $4,000 51% 60% $2,500 40% 40% $3,000 40% $2,000 30% $2,000 $1,500 20% $1,000 20% $1,000 $500 10% 0% $0 $0
Slide 17: OPEX & EBITDA
OPEX & EBITDA (US$ in thousands) OPERATING EXPENSES1 EBITDA2 NPAT3 1H FY22 2H FY22 1H FY23 2H FY23 FY23 FY22 $14,000 $12,232 $0 $'000 $'000 $12,000 $10,592 Underlying EBITDA Loss (5,429) (17,664) $10,000 -$2,000 -$1,795 Depreciation & Amortisation (3,671) (3,017) $8,000 $6,474 $5,416 -$4,000 Gain on
Slide 18: Cash Flow
Cash Flow (US$ in thousands) OPERATING INVESTING FINANCING & CASH BALANCE FY23 FY22 FY23 FY22 FY23 FY22 $'000 $'000 $'000 $'000 $'000 $'000 Cash flows from operating activities Cash flows from investing activities Cash flows from financing activities Proceeds from issue of convertible notes 2,615 -
Slide 19: Balance Sheet
Balance Sheet (US$ in thousands) ASSETS LIABILITIES EQUITY FY23 FY22 FY23 FY22 FY23 FY22 $'000 $'000 $'000 $'000 $'000 $'000 Assets Liabilities Equity Current assets Current liabilities Issued capital 92,468 92,139 Cash and cash equivalents 3,015 7,978 Trade and other payables 2,882 4,115 Reserves (
Slide 20: Promising Outlook
Promising Outlook “ We have come out of FY2023 a much stronger and more focused Expand and diversify pipeline of commercial services projects and recurring revenue company with an exciting pipeline of opportunities in front of us. Continue to build foundation for long-term growth through strategic p
Slide 21: www.lumosdiagnostics.com
www.lumosdiagnostics.com 21
Lumos Diagnostics Holdings — FY2023 Earnings Presentation on 6ix